Advertisement
Canada markets closed
  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • Bitcoin CAD

    88,527.62
    +1,049.45 (+1.20%)
     
  • CMC Crypto 200

    1,334.09
    +21.46 (+1.64%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     
  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     
  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     
  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

ExxonMobil (XOM) Q2 Earnings Top Estimates on Permian Volumes

Exxon Mobil Corporation XOM reported better-than-expected results for second-quarter 2019, courtesy of ramped up liquid volumes in the prolific Permian Basin. This was offset partially by scheduled downtime activities in downstream and chemical operations.

This largest publicly-traded integrated energy company’s earnings per share of 73 cents surpassed the Zacks Consensus Estimate of 68 cents. However, the bottom line declined substantially from the year-earlier 92 cents.

Total revenues of $69,091 million beat the Zacks Consensus Estimate of $65,765. However, the top line deteriorated from the year-ago quarter’s $73,501 million.

Operational Performance

Upstream: Quarterly earnings of $3.3 billion improved from $3 billion a year ago, thanks to an increase in oil equivalent production volumes, partially offset by lower price realizations from liquids and an increase in expenses related to maintenance and exploration in the international market.

ADVERTISEMENT

Total production averaged 3.909 million barrels of oil-equivalent per day (MMBOE/d), higher than 3.647 MMBOE/d a year ago.

Liquid production increased year over year to 2.389 million barrels per day (MMB/D) from 2.212 MMB/D, courtesy of ramped-up activities in the prolific Permian Basin. Also, natural gas production was 9.120 BCF/d (billions of cubic feet per day), up from 8.613 BCF/d a year ago.

Downstream: The segment recorded a profit of $451 million, representing a significant decline from $724 million in the June quarter of 2018. The underperformance can be attributed to scheduled maintenance activities and contraction in industry’s fuel margins.

ExxonMobil's refinery throughput averaged 3.9 million barrels per day (MMB/D), lower than the year-earlier level of 4.1 MMB/D.

Chemical: This unit contributed to the company’s $188 million profit, down from $890 million in the prior-year quarter, induced by soft margins and scheduled maintenance activities.

Financials

During the quarter under review, ExxonMobil generated cash flow of almost $6 billion from operations and asset divestments, down from $8.1 billion a year ago. Owing to significant investments in the prolific Permian Basin, the company’s capital and exploration spending shot up 22% year over year to $8.1 billion.

Zacks Rank & Stocks to Consider

ExxonMobil currently carries a Zacks Rank #5 (Strong Sell). Meanwhile, a few better-ranked players in the energy space include MPLX LP MPLX, Oasis Midstream Partners LP OMP and Plains Group Holdings, L.P. PAGP. All the stocks sport a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

MPLX is likely to see earnings growth of 23.6% through 2019.

Oasis Midstream has an average positive earnings surprise of 0.3% for the past four quarters.

Plains Group is likely to see earnings growth of 7.6% through 2019.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Plains Group Holdings, L.P. (PAGP) : Free Stock Analysis Report MPLX LP (MPLX) : Free Stock Analysis Report Oasis Midstream Partners LP (OMP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research